July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of these partnering organizations on the availability, delivery, organization and...
SCAI
This channel contains news about the Society for Cardiac Angiography and Interventions (SCAI), including coverage of its annual meeting and links to recently released practice guidelines. SCAI is a leading resource in interventional cardiology and cath lab techniques and technologies.
-
-
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin disease, can help reduce coronary plaque.
-
May 14, 2018 — A significant update to the PROGRESS-CTO (PROspective Global Registry for the Study of Chronic Total Occlusion Intervention) International Registry was presented as late-breaking...
-
May 10, 2018 — A new consensus document has been issued to guide the optimal use of ionizing radiation in cardiovascular imaging.
Feature | SCAI | February 25, 2019 | Subhash Banerjee, M.D., FSCAI, Abu-Fadel Mazen, M.D., FSCAI and Rajesh Swaminathan, M.D., FSCAI
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.
Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since...
News | FFR Technologies | July 26, 2018
July 26, 2018 — The Society of Cardiac Angiography and Interventions (SCAI) released a focused update expert...
A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.
Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of...
Two versions of the Abiomed Impella percutaneous ventricular assist device displayed at ACC 2018. Impella is the only device that currently has a FDA indication for use in cardiogenic shock.
Feature | Hemodynamic Support Devices | July 08, 2018 | Emmanouil S. Brilakis, M.D., Ph.D., FSCAI and Srihari S. Naidu, M.D., FSCAI
Cardiogenic shock (CS) is a low-cardiac-output state resulting in life-threatening end-organ hypoperfusion and hypoxia...
Photo courtesy of the American Heart Association
News | Atrial Fibrillation | May 15, 2018
May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception...
News | Peripheral Artery Disease (PAD) | May 15, 2018
May 15, 2018 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to...
News | Cath Lab | May 15, 2018
May 15, 2018 — Revised guidelines incorporating new data on discharge criteria for patients undergoing elective...
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal...
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.
Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin...
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.
Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-...
The Medtronic Endeavor drug-eluting stent was used in the PERSPECTIVE trial to test its durability in chronic total occlusions (CTOs).
News | Chronic Total Occlusion (CTO) | May 14, 2018
May 14, 2018 – One-year outcomes of patients undergoing chronic total occlusion (CTO) percutaneous coronary...
News | Peripheral Artery Disease (PAD) | May 14, 2018
May 14, 2018 — The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the...
News | Chronic Total Occlusion (CTO) | May 14, 2018
May 14, 2018 — A significant update to the PROGRESS-CTO (PROspective Global Registry for the Study of Chronic Total...
